Newsoara Biopharma Signs a Licensing Agreement with Zenith Epigenetics for its ZEN-3694

 Newsoara Biopharma Signs a Licensing Agreement with Zenith Epigenetics for its ZEN-3694

Shots:

  • Zenith Epigenetics will receive $15M as up front and development milestones, ~$63M commercial milestones and up to 6% royalties on sales in the licensed territories which may reduce to 4% based on certain sales milestones are achieved in the territories
  • Newsoara to get rights to develop, commercialize & distribute Zenith’s ZEN-3694 for all indication in China, Hong Kong, Taiwan, and Macau. The license shall expire on a region-by-region basis on the 12th anniversary of the first commercial sale in licensed territories
  • Zenith’s ZEN-3694 is a BET inhibitor, currently being evaluated in P-II study for the treatment of mCRPC & triple-negative breast cancer, administered in combination with other therapies to address resistance and re-sensitize tumors to SOC

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Zenith

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post